Palvella Therapeutics
PVLA
13 hedge funds and large institutions have $46.6M invested in Palvella Therapeutics in 2015 Q2 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
42.64% more ownership
Funds ownership: 0% → 42.64% (+43%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$20M |
| 2 |
Tekla Capital Management
Boston,
Massachusetts
|
+$10.6M |
| 3 |
Lombard Odier Asset Management (USA)
New York
|
+$7.12M |
| 4 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.3M |
| 5 |
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$2.49M |
Top Sellers
PVLA Hedge Fund Activity: Q2 2015 in Review
13 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2015, worth a combined $46.6M.
Buyers outnumbered sellers: 13 funds opened new PVLA positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $20M.
- 13 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $46.6M of Palvella Therapeutics stock for Q2 2015.
- 13 funds opened new Palvella Therapeutics positions in Q2 2015 and 0 closed out, a net change of +13 holders.
- The largest Palvella Therapeutics buyer in Q2 2015 was OrbiMed, an estimated $20M added.
Based on aggregated 13F filings for Q2 2015.